BAKER BROS. ADVISORS LP - 09 Jun 2026 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: PRLD
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 16:44:44 UTC
Prior SEC filing: 10 Jun 2026
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

Key filing fact

BAKER BROS. ADVISORS LP filed Form 4 for Prelude Therapeutics Inc (PRLD) on 10 Jun 2026.

Key facts

This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Prelude Therapeutics Inc (PRLD).
2 reported transactions and 12 derivative rows are listed below.
Accepted by SEC: 10 Jun 2026, 16:44.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001263508 Primary reporting owner

BAKER BROS. ADVISORS LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 10 Jun 2026

CIK 0001551139

667, L.P.

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 10 Jun 2026

CIK 0001580575

Baker Bros. Advisors (GP) LLC

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 10 Jun 2026

CIK 0001363364

Baker Brothers Life Sciences LP

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., /s/ Name: Scott L. Lessing, Title: President
Signature date: 10 Jun 2026

CIK 0001087940

BAKER FELIX

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Felix J. Baker
Signature date: 10 Jun 2026

CIK 0001087939

BAKER JULIAN

Relationship: Director, 10%+ Owner
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Julian C. Baker
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F4, F5, F6, F7, F8, F9

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F4, F5, F6, F7, F8, F9

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F4, F5, F6, F7, F8, F9

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F4, F5, F6, F7, F8, F9

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F4, F5, F6, F7, F8, F9

PRLD transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +38,000
Change %
Price: $0.000000^*
Shares after: 38,000
Date: 09 Jun 2026
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 38,000
Exercise price: $3.94
Footnotes: F1, F2, F4, F5, F6, F7, F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Includes 38,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Prelude Therapeutics Incorporated (the "Issuer") granted by the Issuer to Dr. Paul C. Scherer, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on June 9, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2020 Equity Incentive Plan (the "Incentive Plan"). The Stock Options have a strike price of $3.94 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Dr. Scherer's continued service on the board of directors of the Issuer (the "Board") through such vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 8, 2036.

Footnote F2

Dr. Scherer serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

Footnote F3

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F4

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

Footnote F5

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F6

Pursuant to the policies of the Adviser, Dr. Scherer does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

Footnote F7

Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of the Stock Options.

Footnote F8

The acquisition of Stock Options reported on this form represents a single grant to Dr. Scherer of 38,000 Stock Options on Table II. This grant of 38,000 Stock Options to Dr. Scherer is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

Footnote F9

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC remarks

Dr. Paul C. Scherer, a full-time employee of Baker Bros. Advisors LP, is a director of Prelude Therapeutics Incorporated (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.